IQVIA™ Real-World Insights Bibliography
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
Document Type(s): Article, |
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
Click here for the abstract |
C: Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study, 2023 |
|
L: A: |
English Clinical setting: hospital, Clinical setting: Primary care, |
|
|
|
|
Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
|
Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
|
Affiliations(s): "1
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
2
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
3
Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea
4
Kansai Electric Power Medical Research Institute, Kobe, Japan
5
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
6
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
7
Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
8
Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan
9
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan
10
Department of Cardiovascular Medicine, Saga University, Saga, Japan
11
Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan
12
Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan
13
Boehringer Ingelheim Korea Ltd, Seoul, Korea
14
IQVIA, Espoo, Finland
15
Boehringer Ingelheim International GmbH, Ingelheim, Germany
16
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
17
Kansai Electric Power Hospital, Osaka, Japan
" |
Publication(s): "JDI journal
Virtual Conference: ACC, May 2021"
|
Document Type(s): Article, |
Countries: Japan, Korea, Taiwan, |
Click here for the abstract |
C: Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study, 2023 |
|
L: A: |
English Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis, |
|
|
|
|
Georgraphic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States |
Author(s): Danni Zhao, Jonggyu Baek, Anne L Hume, Emily A McPhillips, and Kate L Lapane
|
Affiliations(s): 1Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA.
2Department of Family Medicine, Alpert Medical School, Brown University, Memorial Hospital of Rhode Island, Providence, RI, USA.
3Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA. |
Publication(s): J Pain Res
. 2022 Feb 11;15:443-454. doi: 10.2147/JPR.S345521. eCollection 2022.
|
Document Type(s): Article, |
Countries: USA, |
Click here for the abstract |
C: Y: |
Drug Utlization Study, Pain, 2022 |
|
L: A: |
English Epidemiological study, Observational study, Public Health, |
|
|
|
|
The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a
|
Author(s): Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group |
Affiliations(s): IQVIA Netherlands, Real World Evidence, Netherlands
b
Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands
c
Medical University of Graz, Graz, Austria
d
Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany
e
St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands |
Publication(s): eNeurologicalSci,
Volume 28,
2022,
100409,
ISSN 2405-6502,
https://doi.org/10.1016/j.ensci.2022.100409.
(https://www.sciencedirect.com/science/article/pii/S2405650222000181)
|
Document Type(s): Article, |
Countries: Austria, Belgium, Netherlands , Slovakia, |
Click here for the abstract |
C: Y: |
Drug safety, Drug Utlization Study, Neurological disorders, 2022 |
|
L: A: |
English Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study, |
|
|
|
|
Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 |
Author(s): Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18, |
Affiliations(s): Pharmacy Department, Mater Dei Hospital, Msida, Malta.
2Exeter College of Medicine and Health, Exeter, UK.
3Department of Medicine, University of Verona, Verona, Italy.
4Real World Solutions Department, IQVIA, Lisbon, Portugal.
5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy.
6Agenzia Regionale di Sanità della Toscana, Florence, Italy.
7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands.
8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy.
9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy.
10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy.
11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.
12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy.
14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France.
16RTI Health Solutions, Barcelona, Spain.
17Democritus University of Thrace, Alexandroupolis, Greece.
18Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
19Data Science Hub, Real World Solutions, IQVIA, London, UK.
20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. |
Publication(s): Pharmacoepidemiol Drug Saf
. 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11.
|
Document Type(s): Article, |
Countries: Denmark, France, Italy, Netherlands, Portugal, Spain, UK, |
Click here for the abstract |
C: Y: |
Drug safety, Drug Utlization Study, 2022 |
|
L: A: |
English Database Study, Review, |
|
|
|
|
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study |
Author(s): Farah Toron 1, Maureen P Neary 2, Timothy W Smith 3, David Gruben 4, William Romero 5, Amy Cha 3, Keyur Patel 1, Simona Z Vasileva 6, Mahreen Ameen 7 |
Affiliations(s): 1Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK.
2Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA.
3Inflammation & Immunology, Pfizer Inc, New York, New York, USA.
4Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA.
5Inflammation & Immunology, Pfizer Ltd, Surrey, UK.
6Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com.
7Royal Free London National Health Services Foundation Trust, London, UK. |
Publication(s): PMID: 33846907 PMCID: PMC8163940 DOI: 10.1007/s13555-021-00519-7
|
Document Type(s): Article, |
Countries: UK, |
Click here for the abstract |
C: Y: |
Dermatology, Drug Utlization Study, Methodology, 2021 |
|
L: A: |
English direct to patient research, direct-to-patient research, Economic evaluation, Population Based Study, Retrospective database analysis, |
|
|
|
|
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
|
Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
|
Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
|
Publication(s): ECTRIMS 2021, Digital, 13-15 October 2021
|
Document Type(s): Abstract, |
Countries: Finland, Sweden, |
Click here for the abstract |
C: Y: |
Drug Utlization Study, Neurological disorders, 2021 |
|
L: A: |
English Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
|
|
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
|
Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
|
Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
|
Publication(s): ECTRIMS 2021, Digital, 13-15 October 2021
|
Document Type(s): Poster, |
Countries: Finland, Sweden, |
Click here for the abstract |
C: Y: |
Drug Utlization Study, Neurological disorders, 2021 |
|
L: A: |
English Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
|
|
Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014
|
Author(s): Pocobelli G, Dublin S, Bobb JF, Albertson-Junkans L, Andrade S, Cheetham TC, Salgado G, Griffin MR, Raebel MA, Smith D, Li DK, Pawloski PA, Toh S, Taylor LG, Hua W, Horn P, Trinidad JP, Boudreau DM
|
Affiliations(s): "L Taylor: EPI OR, RWS, IQVIA; 1Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
2Meyers Primary Care Institute, Worcester, Massachusetts, USA.
3Kaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, Chapman University, School of Pharmacy, Irvine, CA, USA.
4Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
5Institute for Health Research, Kaiser Permanente Colorado, Colorado, USA.
6Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
7Kaiser Foundation Research Institute, Oakland, California, USA.
8Health Partners Institute, Bloomington, Minnesota, USA.
9Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
10Food and Drug Administration, Silver Spring, Maryland, USA."
|
Publication(s): Pharmacoepidemiol Drug Saf. 2021 Nov;30(11):1541-1550. doi: 10.1002/pds.5312.
|
Document Type(s): Article, |
Countries: USA, |
Click here for the abstract |
C: Y: |
Drug Utlization Study, Womens Health, 2021 |
|
L: A: |
English Epidemiological study, Population Based Study, |
|
|
|
|
Monitoring outpatient antibiotic utilization using reimbursement and retail sales data: a population-based comparison in France, 2012-17 |
Author(s): Nhung T H Trinh 1 2, Martin Chalumeau 1 3, Tim A Bruckner 4, Corinne Levy 5 6, Antoine Bessou 2, Dejan Milic 2, Robert Cohen 5 7, Magali Lemaitre 2, Jérémie F Cohen 1 3 |
Affiliations(s): 1Université de Paris, Epidemiology and Statistics Research Center-CRESS, INSERM, Obstetrical, Perinatal and Pediatric Epidemiology research team, F-75004, Paris, France.
2IQVIA, La Défense, France.
3Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Hôpital Necker-Enfants malades, Université de Paris, Paris, France.
4Program in Public Health, University of California, Irvine, CA, USA.
5Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Saint-Maur-des-Fossés, France.
6Clinical Research Centre, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
7Université Paris Est, IMRB-GRC GEMINI, Créteil, France. |
Publication(s): J Antimicrob Chemother
. 2021 Aug 12;76(9):2446-2452. doi: 10.1093/jac/dkab185.
|
Document Type(s): Article, |
Countries: France, |
Click here for the abstract |
C: Y: |
Drug Utlization Study, 2021 |
|
L: A: |
English Population Based Study, |
|
|
|
|
1 of 5
|
|